Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: Potential for significant long-term indirect cost gains (data from a population-based registry)

Annals of the Rheumatic Diseases

Volumn 69, Issue 1, 2010, Pages 126-131

  Augustsson, J ^a   Neovius, M ^b   Cullinane Carli, C ^a   Eksborg, S ^b   Van Vollenhoven, R F ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ADULT; ARTICLE; COST BENEFIT ANALYSIS; DETERIORATION; DISEASE ACTIVITY SCORE 28; DRUG COST; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REGISTER; RHEUMATOID ARTHRITIS; SCORING SYSTEM; WORK CAPACITY;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; DRUG ADMINISTRATION SCHEDULE; EFFICIENCY; EMPLOYMENT; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PATIENT DROPOUTS; RECEPTORS, TUMOR NECROSIS FACTOR; SWEDEN; TUMOR NECROSIS FACTOR-ALPHA; WORKLOAD; YOUNG ADULT;

EID: 73449099289     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.108035     Document Type: Article

References (25)

1. Kobelt G. Health economic issues in rheumatoid arthritis. Scand J Rheumatol 2006;35:415-25.
2. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
3. Feltelius N, Fored CM, Blomqvist P, et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005;64:246-52.
4. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
5. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
6. Landewe R, van der Heijde D, Klareskog L, et al. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006;54:3119- 25.
7. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
8. Yelin E, Trupin L, Katz P, et al. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 2003;48:3046-54.
9. Laas K, Peltomaa R, Kautiainen H, et al. Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment. Ann Rheum Dis 2006;65:924-8.
10. Allaire S, Wolfe F, Niu J, et al. Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out. Arthritis Rheum 2008;59:1082-9.
11. Mittendorf TDB, Sterz R, Cifaldi MA, et al. Personal and economic burden of latestage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective. Rheumatology (Oxford) 2008;47:188-93.
12. Bejarano V, Quinn M, Conaghan PG, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008;59:1467-74.
13. Halpern MT, Cifaldi MA, Kvien TK. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group. Ann Rheum Dis 2009;68:930-7.
14. Askling JFC, Geborek P, Jacobsson LT, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006;65:707-12.
15. van der Heijde DM, van't Hof M, van Riel PL, et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
16. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
17. Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis: Chichester, UK: John Wiley & Sons, 2004.
18. Puolakka K, Kautiainen H, Mottonen T, et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005;52:36-41.
19. Eberhardt K, Larsson BM, Nived K, et al. Work disability in rheumatoid arthritis - development over 15 years and evaluation of predictive factors over time. J Rheumatol 2007;34:481-7.
20. Weinblatt MEKE, Furst DE, Moreland LW, et al. Adalimumab, a fully human antitumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
21. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:1-266.
22. Kobelt G, Eberhardt K, Jonsson L, et al. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56.
23. Verstappen SMBJ, Verkleij H, Buskens E, et al. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 2004;51:488-97.
24. Statistics Sweden. http://www.scb.se (accessed 12 April 2009).
25. Li X, Gignac MA, Anis AH. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changeswhile atwork. MedCare 2006;44:304-10.